company background image
FGEN

FibroGen NasdaqGS:FGEN Stock Report

Last Price

US$9.94

Market Cap

US$927.4m

7D

18.2%

1Y

-53.9%

Updated

15 May, 2022

Data

Company Financials +
FGEN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

FGEN Stock Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

FibroGen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for FibroGen
Historical stock prices
Current Share PriceUS$9.94
52 Week HighUS$30.12
52 Week LowUS$7.81
Beta0.90
1 Month Change-15.91%
3 Month Change-36.28%
1 Year Change-53.90%
3 Year Change-72.21%
5 Year Change-62.84%
Change since IPO-54.82%

Recent News & Updates

Mar 31
Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Shareholder Returns

FGENUS BiotechsUS Market
7D18.2%0.1%-2.5%
1Y-53.9%-21.7%-10.4%

Return vs Industry: FGEN underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: FGEN underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is FGEN's price volatile compared to industry and market?
FGEN volatility
FGEN Average Weekly Movement10.8%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: FGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: FGEN's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993566Enrique Conternohttps://www.fibrogen.com

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy.

FibroGen Fundamentals Summary

How do FibroGen's earnings and revenue compare to its market cap?
FGEN fundamental statistics
Market CapUS$927.38m
Earnings (TTM)-US$281.47m
Revenue (TTM)US$257.71m

3.6x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FGEN income statement (TTM)
RevenueUS$257.71m
Cost of RevenueUS$355.09m
Gross Profit-US$97.39m
Other ExpensesUS$184.09m
Earnings-US$281.47m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.02
Gross Margin-37.79%
Net Profit Margin-109.22%
Debt/Equity Ratio9.8%

How did FGEN perform over the long term?

See historical performance and comparison

Valuation

Is FibroGen undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


33.9%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: FGEN ($9.94) is trading below our estimate of fair value ($15.03)

Significantly Below Fair Value: FGEN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FGEN is overvalued based on its PB Ratio (5.9x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is FibroGen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


24.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FGEN's revenue (18.9% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: FGEN's revenue (18.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FGEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has FibroGen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-24.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: FGEN is currently unprofitable.

Growing Profit Margin: FGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FGEN is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare FGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: FGEN has a negative Return on Equity (-158.12%), as it is currently unprofitable.


Financial Health

How is FibroGen's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: FGEN's short term assets ($524.4M) exceed its short term liabilities ($255.4M).

Long Term Liabilities: FGEN's short term assets ($524.4M) exceed its long term liabilities ($312.5M).


Debt to Equity History and Analysis

Debt Level: FGEN has more cash than its total debt.

Reducing Debt: FGEN's debt to equity ratio has reduced from 10% to 9.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FGEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: FGEN has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 2.8% each year.


Dividend

What is FibroGen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate FGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as FGEN has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Enrique Conterno (54 yo)

2.33yrs

Tenure

US$10,385,103

Compensation

Mr. Enrique A. Conterno is the Chief Executive Officer and Director at FibroGen, Inc. since January 6, 2020. He served as President of Lilly USA from January 2017 to 2019. Mr. Conterno served as President...


CEO Compensation Analysis

Compensation vs Market: Enrique's total compensation ($USD10.39M) is above average for companies of similar size in the US market ($USD3.88M).

Compensation vs Earnings: Enrique's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: FGEN's management team is considered experienced (4 years average tenure).


Board Members

Experienced Board: FGEN's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

FibroGen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: FibroGen, Inc.
  • Ticker: FGEN
  • Exchange: NasdaqGS
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$927.378m
  • Shares outstanding: 93.30m
  • Website: https://www.fibrogen.com

Number of Employees


Location

  • FibroGen, Inc.
  • 409 Illinois Street
  • San Francisco
  • California
  • 94158
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.